Elevated intracranial dopamine impairs the glutamate-nitric oxide-cyclic guanosine monophosphate pathway in cortical astrocytes in rats with minimal hepatic encephalopathy

SAIDAN DING1*, WEILONG HUANG2*, YIRU YE3, JIANJING YANG2, JIANGNAN HU2, XIAOBIN WANG2, LEPING LIU1, QIN LU2 and YUANSHAO LIN4

1Zhejiang Provincial Key Laboratory of Aging and Neurological Disease Research, Department of Surgery Laboratory, The First Affiliated Hospital of Wenzhou Medical University; 2Neurosurgery Department, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000; 3Department of Computer, Wenzhou Medical University, Wenzhou, Zhejiang 325000; 4First Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China

Received September 26, 2013; Accepted April 16, 2014

DOI: 10.3892/mmr.2014.2386

Abstract. In a previous study by our group memory impairment in rats with minimal hepatic encephalopathy (MHE) was associated with the inhibition of the glutamate-nitric oxide-cyclic guanosine monophosphate (Glu-NO-cGMP) pathway due to elevated dopamine (DA). However, the effects of DA on the Glu-NO-cGMP pathway localized in primary cortical astrocytes (PCAs) had not been elucidated in rats with MHE. In the present study, it was identified that when the levels of DA in the cerebral cortex of rats with MHE and high-dose DA (3 mg/kg)-treated rats were increased, the co-localization of N-methyl-D-aspartate receptors subunit 1 (NMDAR1), calmodulin (CaM), nitric oxide synthase (nNOS), soluble guanylyl cyclase (sGC) and cyclic guanine monophosphate (cGMP) with the glial fibrillary acidic protein (GFAP), a marker protein of astrocytes, all significantly decreased, in both the MHE and high-dose DA-treated rats (P<0.01). Furthermore, NMDA-induced augmentation of the expression of NMDAR1, CaM, nNOS, sGC and cGMP localized in PCAs was decreased in MHE and DA-treated rats, as compared with the controls. Chronic exposure of cultured cerebral cortex PCAs to DA treatment induced a dose-dependent decrease in the concentration of intracellular calcium, nitrites and nitrates, the formation of cGMP and the expression of NMDAR1, CaM, nNOS and sGC/cGMP. High doses of DA (50 µM) significantly reduced NMDA-induced augmentation of the formation of cGMP and the contents of NMDAR1, CaM, nNOS, sGC and cGMP (P<0.01). These results suggest that the suppression of DA on the Glu-NO-cGMP pathway localized in PCAs contributes to memory impairment in rats with MHE.

Introduction

Minimal hepatic encephalopathy (MHE) refers to the subtle changes in cognitive function, electrophysiological parameters, cerebral neurochemical/neurotransmitter homeostasis, cerebral blood flow, metabolism and fluid homeostasis that are observed in patients with cirrhosis, who have no clinical evidence of hepatic encephalopathy (1). The glutamate-nitric oxide-cyclic guanine monophosphate (Glu-NO-cGMP) pathway is involved in certain types of learning and memory (2,3). Activation of N-methyl-D-aspartate receptors subunit 1 (NMDAR1) by glutamate increases calcium in postsynaptic neurons. Calcium binds to calmodulin (CaM) and activates neuronal nitric oxide synthase (nNOS), increasing NO, which activates soluble guanylyl cyclase (sGC), increasing cyclic guanine monophosphate (cGMP), part of which is released to the extracellular space and is functionally important in learning and memory (2). A previous study by our group (4) identified that a catechol-O-methyltransferase (COMT) inhibitor, a protein involved in the accumulation of dopamine (DA), was upregulated in cirrhotic livers in rats with MHE by 2-dimensional gel electrophoresis/mass spectrometry (2-DE/MS). Furthermore, the levels of DA in cirrhotic livers, serum and the hippocampli in the MHE group were notably increased, and the Glu-NO-cGMP memory pathway in hippocampal neurons was inhibited by the elevation of DA in vivo and in vitro. Therefore, it was hypothesized that the pathogenesis of MHE may be associated with the elevation in DA characteristic of cirrhotic livers. Furthermore, the study demonstrated that the DA levels were increased in cirrhotic livers and that it crossed the blood-brain barrier, migrated into the brains of rats with MHE and inhibited their learning and memory ability by blocking the Glu-NO-cGMP pathway in
neurons (4). However, whether astrocytes were involved in the pathogenesis of MHE remained elusive.

One type of astrocyte, expressing glutamate receptors, responds to the synaptic release of glutamate via channel-mediated currents and is involved in the function of the Glu-NO-cGMP pathway. Activation of mGluR3 receptors in striatal neurons (5), hippocampal neurons (6), cerebellar granule cell neurons (7) and rat cerebellar astrocytes (8) is accompanied by a reduction in the levels of cyclic adenosine monophosphate (cAMP). In the majority of tissues, NO acts as an intracellular signaling molecule and is formed in all brain cells, including astrocytes, by NOS from l-arginine (9). The major physiological receptor for NO is sGC, an αβ heterodimer that catalyses the conversion of guanosine triphosphate (GTP) to cGMP and which acts as a secondary messenger, modulating the activity of cGMP-dependent protein kinases, cyclic nucleotide phosphodiesterases and cyclic nucleotide-gated channels (10). Several studies have suggested that astrocytes integrate learning and memory in the cerebral cortex by having a direct role in the modulation of synaptic plasticity and long-term potentiation (11).

The present study delineated the role of the Glu-NO-cGMP pathway localized in astrocytes in MHE-associated memory loss, particularly focusing on the effect of elevated DA from cirrhotic liver in the brains of an MHE in vivo model.

Materials and methods

MHE models and treatments. A total of 50 Sprague-Dawley rats (Experimental Animal Center of The Chinese Academy of Sciences in Shanghai, Shanghai, China) weighing 220-250 g were used. The present study was approved by the ethics committee of the First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China) regarding the care and use of animals for experimental procedures. Rats were housed under controlled conditions of temperature (24±1°C) and light (12 h light starting at 07:00 am). Prior to the experimental stage, all animals were subject to a series of behavioral tests including Y-maze (YM), open-field (OF), elevated-plus maze (EPM) and water-finding task (WFT) tests. There was a 15 min interval between each behavioral test for each rat. The normalized values of these behavioral tests were obtained. Rats were then randomly divided into two groups; the control group (n=20) and the thioacetamide (TAA) group (n=30). MHE was induced by intraperitoneal injection (i.p.) of TAA (200 mg/kg in normal saline; Sigma-Aldrich, St. Louis, MO, USA) twice a week for a period of eight weeks. Then, the rats were subjected to the same behavioral tests again. Rats included in the MHE group were required to meet the following criteria: i) The values of one of the behavioral tests in the MHE group being significantly different from those of the control group and ii) the EEG revealing no typical slow wave of hepatic encephalopathy (12). At 24 h following MHE induction, NMDA (0.3 mM) was also administered to the rats for 30 min by intraperitoneal injection. Liver, serum and cerebral cortex were collected for fluorescent staining, immunoblotting and determination of DA.

DA-injected rat models and treatments. Rats were administered DA hydrochloride (0.3 and 3 mg/kg; Sigma-Aldrich) by i.p. injection twice per week for four weeks. All of the rats were subjected to the OF, YM, EPM and WFT tests. Following the final injection, NMDA (0.3 mM; Sigma-Aldrich) was also administered to the rats for 30 min by intraperitoneal injection. Liver, serum and cerebral cortex specimens were collected for fluorescent staining, immunoblotting and determination of DA.

Behavioral tests. The OF test was performed as previously described (13). Briefly, rats were individually placed at the center of a 10x10 cm plastic grid (with 20 cm interval black grids) surrounded by a 20-cm wall and allowed to move freely for 3 min. Ambulation was measured and defined as the total number of grid line crossings (13).

The apparatus for the YM test was composed of gray plastic, with each arm being 40 cm long, 12 cm high, 3 cm wide at the base and 10 cm wide at the top. The three arms were connected at an angle of 120°. Rats were individually placed at the end of one arm and allowed to explore the maze freely for 8 min. Total arm entries and spontaneous alternation percentage (SA%) were measured. SA% was defined as the ratio of the arm choices that differed from the previous two choices (‘successful choices’) to the total choices during the run (‘total entry minus two’ because the first two entries were not evaluated). For example, if a mouse made 10 entries, such as 1-2-3-2-1-2-3-2-1, there were 5 successful choices in 8 total choices (10 entries minus 2; 13,14).

The EPM test apparatus was composed of four crossed arms. Two arms were open (50x10 cm grey plastic floor plate without walls), whereas the other two were closed (same floor plates with 20 cm-high transparent acrylic wall). The maze was set at a height of 100 cm above the floor. Rats were allowed to explore the maze freely for 90 sec. The parameters that were examined were as follows: i) The transfer latency (the time elapsed until the first entry to a closed arm); ii) the duration of the first stay in a closed arm (the time from the first entry to a closed arm to the first escape from the arm) and iii) the cumulative time spent in the open/closed arms (13,15).

The WFT test was performed to analyze latent learning or retention of spatial attention ability in the rats. The testing apparatus consisted of a grey plastic rectangular open field (50x30 cm, with a black 10 cm² grid) with a 15 cm high wall and a cubic alcove (10x10x10 cm), which was attached to the center of one longer wall. A drinking tube was inserted through a hole at the center of the alcove ceiling, with the tip of the tube placed at 5 cm for training or at 7 cm for the trial from the floor. A mouse was first placed at the near-right corner of the apparatus and allowed to explore freely for 3 min. Rats were excluded from the analysis when they were not able to locate the tube within the 3 min exploration. Following completion of the training, the rats were deprived of water for 24 h. In the trial session, rats were again individually placed at the same corner of the apparatus and allowed to locate and drink the water in the alcove. The elapsed time until the first entry into the alcove (entry latency, EL), until the first touching, sniffing or licking of the water tube (contacting latency, CL) and until the initiation of drinking from the water tube (drinking latency, DL) were measured (13,16,17).

Histopathology. Liver tissues were fixed in 10% formalin for 24 h and then paraffin-embedded in an automated tissue
Changes in intracellular Ca\(^{2+}\) in PCAs. The changes in intracellular Ca\(^{2+}\) were monitored in single PCAs by confocal microscopy using Fluo-3/AM as previously described (20).
Figure 1. Memory impairment and elevated DA in MHE models. (A) Hematoxylin and eosin (scale bar, 50 µm) and (B) Sirius red staining (scale bar, 100 µm) of liver sections from the control and TAA-treated rats. (C) Ambulation in open-field test of the control and TAA-treated rats (left, pretreatment; right, eight-week treatment). (D) SA% in YM of the control and TAA-treated rats (left, pretreatment; right, 8-week treatment). (E) Results of EPM (TL, transfer latency; first stay, duration of the first stay; open, time spent in the open arms; closed, time spent in the closed arms). (F) Results of the WFT test (EL, entry latency; CL, contacting latency; DL, drinking latency). (G) The cerebral signal of rats observed in the scalp EEG falls in the Alpha (8-13 Hz) range in the control and MHE rats. Levels of DA in (H) the liver, (I) serum and (J) cerebral cortex analyzed in the control and MHE groups. Data are presented as the mean ± standard deviation. *P<0.05, **P<0.01 vs. control treatment by Dunnett's post-hoc test. DA, dopamine; MHE, minimal hepatic encephalopathy; YM, Y-maze; SA%, spontaneous alternation percentage; EPM, elevated-plus maze; WFT, water-finding task; TAA, thioacetamide.

Figure 2. Effect of intracranial elevated DA on memory impairment. (A) Ambulation in OF of control and DA (0.3 and 3 mg/kg)-treated rats (left, pretreatment; right, eight-week treatment). (B) SA% in YM of control and DA (0.3 and 3 mg/kg)-treated rats (left, pretreatment; right, eight-week treatment). (C) Results of EPM (TL, transfer latency; first stay, duration of the first stay; open, time spent in the open arms; closed, time spent in the closed arms). (D) Results of WFT (EL, entry latency; CL, contacting latency; DL, drinking latency). (E) No Theta (4-7 Hz) or Delta (<4 Hz) bands (slow wave) were observed in EEG of DA-treated rats. Levels of DA in the (F) serum and (G) cerebral cortex analyzed in the control and DA-treated groups. Data are presented as the mean ± standard deviation. *P<0.05, **P<0.01 vs. control treatment by Dunnett's post-hoc test. DA, dopamine; MHE, minimal hepatic encephalopathy; YM, Y-maze; SA%, spontaneous alternation percentage; EPM, elevated-plus maze; WFT, water-finding task; EEG, electroencephalogram.
Results

Memory impairment and elevation of intracranial DA levels in MHE models. H&E and Sirius red staining in the livers of TAA-treated rats revealed inflammatory cell infiltration around the portal area, with collagen deposition or fibrous septa formation (Fig. 1A and B), suggesting that the liver fibrosis model was successfully established.

Rats were then subjected to a series of behavioral tests, including OF, YM, EPM and WFT tests. There were significant differences in the voluntary activities in the OF test between the MHE and control groups following treatment (Fig. 1C). The SA% in the YM of the TAA-treated rats was significantly decreased (P<0.01), compared with that of the control rats (Fig. 1D). In the EPM test, TAA-treated rats remained in the open arms for significantly longer than in the closed arms, as compared with the controls (Fig. 1E). In the WFT test, significant delays in EL, CL and DL were detected in the TAA-treated rats as compared with the controls (Fig. 1F). In the EEG tests, 6/25 TAA-treated rats exhibited slow wave (Theta =4-7 Hz or Delta <4 Hz wave; Fig. 1G). Therefore, the incidence of MHE in the TAA group was 76.0% (19/25).

Considering that the increased levels of DA in the liver (Fig. 1H), serum (Fig. 1I) and cerebral cortex (Fig. 1J) of MHE rats were observed in a previous study by our group (4), the present study examined whether the concentration of DA in
the liver, serum and cerebral cortex of rats with MHE would exhibit similar trends. The data were consistent with those of the previous study, confirming the earlier results (Fig. 1H). The results confirmed that DA, when elevated in the liver, crossed the blood-brain barrier and permeated into the brains of rats with MHE, as previously observed.

Figure 4. The Glu-NO-cGMP pathway was inhibited by DA (0.3 and 3 mg/kg) in astrocytes of the cerebral cortex *in vivo*. Double immunofluorescent staining of cerebral cortex of control and DA (0.3 and 3 mg/kg) -treated rats with the absence or the presence of NMDA using antibodies against GFAP (red) and (A) NMDAR1, (B) CaM, (C) nNOS, (D) sGC and (E) cGMP (green) (scale bar, 25 µm). Glu-NO-cGMP, glutamate-nitric oxide-cyclic guanosine monophosphate; NMDAR1, N-methyl-D-aspartate receptors subunit 1; DA, dopamine; CaM, calmodulin; nNOS, nitric oxide synthase; sGC, soluble guanylyl cyclase; cGMP, cyclic guanine monophosphate; GFAP, glial fibrillary acidic protein.
Confirmation of memory impairment caused by elevation of intracranial DA. To confirm whether memory impairment in rats with MHE was associated with DA transported into the brain, normal rats were subjected to an i.p. injection of DA (low dose, 0.3 mg/kg and high dose, 3 mg/kg). At a week following the injection, all rats were again subjected to behavioral tests, including OF, YM, EPM and WFT tests. The mean voluntary activities in the OF test were significantly increased following high-dose DA treatment (Fig. 2A). The SA% (P<0.01) in the YM test was significantly decreased in high-dose DA-treated rats (Fig. 2B). In the EPM test, the high-dose DA-treated rats remained in the open arms for significantly longer and spent a shorter time in the closed arms as compared with the controls (Fig. 2C). In the WFT, EL, CL and DL tests, the responses were significantly delayed in the high-dose DA-treated rats as compared with the controls (Fig. 2C). The control and DA-treated rats demonstrated an Alpha (8-13 Hz) band in the EEG tests (Fig. 2E).

It was also observed that the levels of DA in the serum (Fig. 2F) and cerebral cortex (Fig. 2G) were significantly elevated following treatment with a high dose of DA (P<0.01), confirming that when blood levels were high, DA crossed the blood-brain barrier, permeated the brains and subsequently attenuated cognitive function in rats.

Inactivation of Glu-NO-cGMP pathway in astrocytes of the cerebral cortex by DA in vivo. A previous study by our group identified that memory impairment in rats with MHE was associated with the inactivation of the Glu-NO-cGMP pathway in neurons by high doses of DA in the brain (4). Therefore, the present study examined whether the inactivation of the Glu-NO-cGMP pathway in astrocytes contributed to memory impairment in rats with MHE. The proteins of the Glu-NO-cGMP pathway (NMDAR1, CaM, nNOS, sGC and cGMP) were co-localized with GFAP in the cerebral cortex. The co-localization indicated that the four proteins were significantly decreased in the rats with MHE, as compared with the normal rats (Fig. 3A-E), indicating that the inhibition of the Glu-NO-cGMP pathway in astrocytes of rats with MHE was associated with memory impairment. As expected, the NMDAR1, CaM, nNOS, sGC and cGMP levels were substantially increased following i.p. injection of NMDA (Fig. 3E). The augmentation of NMDAR1, CaM, nNOS, sGC and cGMP levels induced by NMDA was inhibited in rats with MHE (Fig. 3A-E).

Following this, it was determined whether DA was involved in the inhibition of the Glu-NO-cGMP pathway in astrocytes in the DA (0.3 and 3 mg/kg)-treated rats. DA treatment also induced a dose-dependent decrease in the expression of the four proteins localized in the astrocytes of the cerebral cortex of rats. The co-localization demonstrated that the four proteins were highly expressed in the astrocytes of normal and low-dose DA-treated rats and weakly expressed in the astrocytes of high-dose DA-treated rats (Fig. 4A-E), indicating high-dose DA-induced inhibition of the Glu-NO-cGMP pathway in the astrocytes of the cerebral cortex of rats. Furthermore, it was identified that high-dose DA (3 mg/kg) decreased NMDA-mediated augmentation of...
DING et al.: DOPAMINE IMPAIRS Glu-NO-cGMP PATHWAY

1222

Inactivation of the Glu-NO-cGMP pathway in PCAs by DA. To confirm the inhibition of the activation of the Glu-NO-cGMP pathway by DA in PCAs, the levels of intracellular Ca²⁺, nitrites and nitrates and cGMP in DA-treated PCAs were assessed. NMDA (0.3 mmol/l) was added to the normal and DA-treated PCAs. As revealed in Fig. 5Aa, NMDA induced increases in calcium levels in normal PCAs. Chronic exposure to high-dose DA significantly decreased NMDA-induced increases in calcium (Fig. 5Ad). Basal concentrations of nitrites and nitrates were lower in high-dose DA-treated PCAs (1.15±0.89 mol/l) than in the controls (2.51±0.56 mol/l) (Fig. 5B). NMDA increased the levels of nitrites and nitrates in the control PCAs. NMDA-induced elevation of NO was also impaired in DA-treated PCAs (Fig. 5B).

DA treatment induced a dose-dependent decrease in the formation of cGMP in PCAs. As shown in Fig. 5C, the content of basal cGMP in PCAs following low-dose DA treatment (5 µM) revealed no difference compared with those of the controls. Chronic exposure to high levels of DA significantly decreased the basal cGMP concentration. The addition of NMDA increased cGMP levels in the control PCAs, 5 and 50 µM DA-treated PCAs to 12.31±2.02, 11.79±1.84 and 6.53±1.12 pmol/mg protein, respectively (Fig. 5C), indicating a significant reduction of 38% for 50 µM DA treatment in the function of the Glu-NO-cGMP pathway.

Following this, the effect of DA on the expression of proteins of the Glu-NO-cGMP pathway was confirmed by immunostaining and immunoblot analysis of NMDAR1, CaM, nNOS, sGC and cGMP in PCAs. DA treatment induced a dose-dependent decrease in the expression of the four proteins in PCAs. The results of the immunoblotting analyses revealed that the expression of the four proteins was downregulated in PCAs exposed to high-dose DA (50 µM) as compared with the control group (Fig. 6A). As demonstrated in Fig. 6B, immunofluorescent assessment revealed that low-dose DA treatment (5 µM) failed to attenuate the number of NMDAR1, CaM, nNOS or sGC immuno-reactive PCAs. By contrast, the high-dose DA treatment (50 µM) successfully decreased the expression of the four proteins. The addition of NMDA upregulated the expression of the four proteins in PCAs, which was an effect that was inhibited by high-dose DA (Fig. 6A and B). These results suggested that DA inhibits the function of the whole Glu-NO-cGMP pathway.

Discussion

In the present study, it was demonstrated that chronic stimulation of astrocytes in the cerebral cortex by toxic DA significantly deteriorated the expression of proteins involved in the Glu-NO-cGMP pathway. The results revealed that chronic exposure to DA affected the Glu-NO-cGMP pathway in astrocytes of the rat cerebral cortex in vivo at different stages. Exposure to DA significantly reduced the levels of NMDAR1, CaM, nNOS, sGC and cGMP (Fig. 3) and the acti-
vation of NMDAR1, CaM, nNOS, sGC and cGMP by NMDA (Fig. 1). This effect may subsequently contribute to the reduced formation of cGMP. Therefore, the present study provided the first evidence, to the best of our knowledge, suggesting that the Glu-NO-cGMP pathway localized in astrocytes may be important in the pathogenesis of DA-associated memory impairment in rats with MHE.

Chronic exposure of rats to DA appeared to affect the Glu-NO-cGMP pathway at different stages. A number of studies have suggested that high concentrations of DA reduce NMDAR1-mediated currents and postsynaptic potentials in pyramidal neurons (23-25). Another recent study reported that the direct inhibition of NMDAR1 by D1 ligands (DA) is due to the blockade of the channel pore (26). Several previous studies have demonstrated that DA inhibits NMDA receptor-mediated nNOS stimulation, and thus has a role in nNOS-NO signaling in the generation of striatal cGMP (27-33). NO is partially controlled by nigrostriatal DA input and affects striatal functions (34-37). One study suggested that the parkinsonian state is associated with an abnormal NO/sGC cascade. The DA-deprived striatum revealed a reduction in the standard NO-mediated inhibition (38). The present study demonstrated that the decreased content of NMDAR1, CaM, nNOS, sGC and cGMP, and the impairment of NMDA-induced activation of NMDAR1, CaM, nNOS, sGC and cGMP occurred in astrocytes treated with high concentrations of DA, suggesting that DA was responsible for impaired activation of any of the proteins of the Glu-NO-cGMP pathway and was involved in the impairment of cognitive ability.

In conclusion, the present study provided evidence for a novel theory accounting for memory dysfunction in MHE. The results demonstrated that high DA levels in cirrhotic livers led to elevated DA levels in the brains of MHE models, and that the subsequent DA-dependent inactivation of the Glu-NO-cGMP pathway in astrocytes triggered memory impairment in the rats with MHE. The effect of DA on the impairment of the Glu-NO-cGMP pathway in astrocytes provided new insights that facilitate the understanding of the function of astrocytes. These results provided evidence of not only a novel pathological hallmark of MHE but also a candidate target for MHE therapy. Further investigations should focus on the downstream cascades of the Glu-NO-cGMP pathway that may also be involved in DA-induced memory impairment in MHE.

Acknowledgements

This study was funded by the Natural Science Foundation of China (81300308 and 81301014).

References

1. Tan HH, Lee GH, Thia KT, Ng HS, Chow WC and Lui HF: Minimal hepatic encephalopathy runs a fluctuating course: results from a three-year prospective cohort follow-up study. Singapore Med J 50: 255-260, 2009.

2. Yamada K, Hiramatsu M, Noda Y, et al: Role of nitric oxide and cyclic GMP in the dazocilpine-induced impairment of spontaneous alternation behavior in mice. Neuroscience 74: 365-374, 1996.

3. Erceg S, Monfort P, Hernandez-Viadel M, Rodrigo R, Montoliu C and Felipo V: Oral administration of sildenafl restores learning ability in rats with hyperammonemia and with portalacaval shunts. Hepatology 41: 299-306, 2005.

4. Ding S, Liu L, Jing H, et al: Dopamine from cirrhotic liver contributes to the impaired learning and memory ability of hippocampus in minimal hepatic encephalopathy. Hepatol Int 7: 922-936, 2013.

5. Manzoni O, Prezeau L, Sladzeczky F and Bockaert J: Trans-ACPD inhibits cAMP formation via a pertussis toxin-sensitive G-protein. Eur J Pharmacol 225: 357-358, 1992.

6. Schoepf DD, Johnson BG and Monn JA: Inhibition of cyclic AMP formation by a selective metabolotropic glutamate receptor agonist. J Neurochem 58: 1184-1186, 1992.

7. Wroblewska B, Wroblewski JT, Saab OH and Neale JH: N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells. J Neurochem 61: 943-948, 1993.

8. Wroblewska B, Sant MR and Neale JH: N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 24: 172-179, 1998.

9. Breit DS and Snyder SH: Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 63: 175-195, 1994.

10. Bellamy TC and Garthwaite J: The receptor-like properties of nitric oxide-activated soluble guanylyl cyclase in intact cells. Mol Cell Biochem 230: 165-176, 2002.

11. Newman EA: Propagation of intercellular calcium waves in retinal astrocytes and Müller cells. J Neurosci 21: 2215-2223, 2001.

12. Liu QL and Zhang MH: Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats. World J Gastroenterol 11: 908-911, 2005.

13. Kawasumi M, Chiba T, Yamada M, et al: Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer’s disease in aged mice. Eur J Neurosci 19: 2826-2838, 2004.

14. Yamada M, Chiba T, Sasabe J, et al: Implanted cannula-mediated repetitive administration of Abeta25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav Brain Res 164: 139-146, 2005.

15. Itoh J, Nabeshima T and Kameyama T: Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology (Berl) 101: 27-33, 1990.

16. Ichihara K, Nabeshima T and Kameyama T: Differential effects of pimozide and SCH 23390 on acquisition of learning in mice. Eur J Pharmacol 164: 189-195, 1989.

17. Mamiya T, Noda Y, Nishi M, Takeshima H and Nabeshima T: Enhancement of spatial attention in nociceptin/orphanin FQ receptor-knockout mice. Brain Res 783: 236-240, 1998.

18. Colado MJ, Ormazabal MJ, Alfaro MJ and Martin MJ: Effect of Bay K 8644 on the synthesis and metabolism of dopamine and 5-hydroxytryptamine in various brain areas of the rat. J Pharm Pharmacol 45: 220-227, 1993.

19. Bernabeu R, Schmitz P, Faillace MP, Izquierdo I and Medina JH: Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning. Neuroreport 7: 585-588, 1996.

20. Marcaida G, Miñana MD, Burgal M, Grisolia S and Felipo V: Ammonia prevents activation of NMDA receptors by glutamate in rat cerebellar neuronal cultures. Eur J Neurosci 7: 2389-2396, 1995.

21. Verdon CP, Burton BA and Prior RL: Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite. Anal Biochem 224: 502-508, 1995.

22. Yi Z, Petralia RS, Fu Z, et al: The role of the PDZ protein GIPC in regulating NMDA receptor trafficking. J Neurosci 27: 11663-11675, 2007.

23. Castro NG, de Mello MC, de Mello FG and Arcarava Y: Direct inhibition of the N-methyl-D-aspartate receptor channel by dopamine and (+)-SKF38393. Br J Pharmacol 126: 1847-1855, 1999.

24. Zheng P, Zhang XX, Bunney BS and Shi WX: Opposite modulation of cortical N-methyl-D-aspartate receptor-mediated responses by low, and high concentrations of dopamine. Neurosci 91: 527-535, 1999.

25. Seamans JK and Yang CR: The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74: 1-58, 2004.

26. Cui C, Xu M and Atzori M: Voltage-dependent block of N-methyl-D-aspartate receptors by dopamine D1 receptor ligands. Mol Pharmacol 70: 1761-1770, 2006.
27. Altar CA, Boyar WC and Kim HS: Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP. Eur J Pharmacol 181: 17-21, 1990.
28. Di Stefano A, Sozio P, Cacciatore I, et al: Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists. J Med Chem 48: 2646-2654, 2005.
29. Hoque KÊ, Indorkar RP, Sammut S and West AR: Impact of dopamine-glutamate interactions on striatal neuronal nitric oxide synthase activity. Psychopharmacology (Berl) 207: 571-581, 2010.
30. Morris RG, Hagan JJ and Rawlins JN: Allocentric spatial learning by hippocampectomised rats: a further test of the 'spatial mapping' and 'working memory' theories of hippocampal function. Q J Exp Psychol B 38: 365-395, 1986.
31. Park DJ and West AR: Regulation of striatal nitric oxide synthesis by local dopamine and glutamate interactions. J Neurochem 111: 1457-1465, 2009.
32. Sammut S, Dec A, Mitchell D, Linardakis J, Ortiguela M and West AR: Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism. Neuropsychopharmacology 31: 493-505, 2006.
33. Siuciak JA, McCarthy SA, Chapin DS, et al: Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51: 374-385, 2006.
34. Calabresi P, Centonze D, Gubellini P, Marfia GA, Pisani A, Sancesario G and Bernardi G: Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog Neurobiol 61: 231-265, 2000.
35. Centonze D, Gubellini P, Pisani A, Bernardi G and Calabresi P: Dopamine, acetylcholine and nitric oxide systems interact to induce corticostratal synaptic plasticity. Rev Neurosci 14: 207-216, 2003.
36. Kawaguchi Y: Neostriatal cell subtypes and their functional roles. Neurosci Res 27: 1-8, 1997.
37. West AR and Grace AA: Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 22: 294-304, 2002.
38. Galati S, D’angelo V, Scarnati E, et al: In vivo electrophysiology of dopamine-denervated striatum: focus on the nitric oxide/cGMP signaling pathway. Synapse 62: 409-420, 2008.